류마티스 관절염을 가진 만성신질환 환자에서 저용량 methotrexate 투여 후 발생한 중증 범혈구 감소증 2예
Two Cases of Severe Pancytopenia Associated with Low-Dose Methotrexate Therapy in Patients with Chronic Kidney Disease and Rheumatoid Arthritis
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Due to its efficacy and tolerability, low dose oral methotrexate(MTX) therapy has been widely used for treatment of rheumatoid arthritis(RA). However, it can rarely cause serious, life-threatening hematologic toxicities, such as pancytopenia. We report here on two patients with chronic kidney disease(CKD), who developed severe pancytopenia after 5 years (cumulative dose 1,240mg) and 4 years(cumulative dose 1,320mg) of low dose MTX therapy for treatment of RA, respectively. Both patients presented with renal insufficiency, hypoalbuminemia, concurrent use of nonsteroidal anti-inflammatory drugs, and elevated mean corpuscular volume of red blood cells(RBCs), all of which are known as risk factors of MTX-induced pancytopenia. Despite receiving treatment, which included RBC and platelet transfusions, antibiotic therapy, granulocyte colony stimulating factor, and leucovorin rescue, one patient died of sepsis. Based on our case study, prompt investigation of risk factors associated with MTX toxicity is required for all patients receiving MTX therapy. MTX treatment, even at a low dose, should be discontinued in patients with advanced CKD.
Abstract
Due to its efficacy and tolerability, low dose oral methotrexate(MTX) therapy has been widely used for treatment of rheumatoid arthritis(RA). However, it can rarely cause serious, life-threatening hematologic toxicities, such as pancytopenia. We report here on two patients with chronic kidney disease(CKD), who developed severe pancytopenia after 5 years (cumulative dose 1,240mg) and 4 years(cumulative dose 1,320mg) of low dose MTX therapy for treatment of RA, respectively. Both patients presented with renal insufficiency, hypoalbuminemia, concurrent use of nonsteroidal anti-inflammatory drugs, and elevated mean corpuscular volume of red blood cells(RBCs), all of which are known as risk factors of MTX-induced pancytopenia. Despite receiving treatment, which included RBC and platelet transfusions, antibiotic therapy, granulocyte colony stimulating factor, and leucovorin rescue, one patient died of sepsis. Based on our case study, prompt investigation of risk factors associated with MTX toxicity is required for all patients receiving MTX therapy. MTX treatment, even at a low dose, should be discontinued in patients with advanced CKD.
참고문헌 (17)
- Kalantzis A, "Oral effects of low- dose methotrexate treatment", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 100, pp.52~62 (2005)
- Swierkot J, "Methotrexate in rheumatoid arthritis", Pharmacol Rep, 58, pp.473~492 (2006)
- Preet Singh Y, "Low-dose methotrexate-induced pancytopenia", Clin Rheumatol, 26, pp.84~87 (2007)
- Cheung KK, "Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate", J Clin Rheumatol, 15, pp.177~180 (2009)
- Park GT, "A case of pancytopenia secondary to low-dose pulse methotrexate therapy in a patient with rheumatoid arthritis and renal insufficiency", Korean J Intern Med, 14, pp.85~87 (1999)
- 고선희, "신기능이 저하된 환자에서 저용량 메토트렉세이트에 의한 범혈구감소증", 대한내과학회지, 77(5), pp.637~642 (2009), 대한내과학회
- Weinblatt ME, "Toxicity of low dose methotrexate in rheumatoid arthritis", J Rheumatol Suppl, 12(Suppl 12), pp.35~39 (1985)
- Lim AY, "Methotrexate- induced pancytopenia: serious and under- reported? Our experience of 25 cases in 5 years", Rheumatology (Oxford), 44, pp.1051~1055 (2005)
- Gutierrez-Urena S, "Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis", Arthritis Rheum, 39, pp.272~276 (1996)
- Kuitunen T, "Pancytopenia induced by low-dose methotrexate. a study of the cases reported to the finnish adverse drug reaction register from 1991 to 1999", Scand J Rheumatol, 34, pp.238~241 (2005)
- Ellman MH, "Low-dose methotrexate and severe neutropenia in patients undergoing renal dialysis", Arthritis Rheum, 33, pp.1060~1061 (1990)
- MacKinnon SK, "Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis", Semin Arthritis Rheum, 15, pp.119~126 (1985)
- Bruyn GA, "Pancytopenia related eosinophilia in rheumatoid arthritis: a specific methotrexate phenomenon?", J Rheumatol, 22, pp.1373~1376 (1995)
- Yang CP, "Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature", Ren Fail, 28, pp.95~97 (2006)
- Kondo H, "Benefit of simultaneous rhG-CSF and methylprednisolone ‘pulse’ therapy for methotrexate-induced bone marrow failure in rheumatoid arthritis", Int J Hematol, 65, pp.159~163 (1997)
- Wall SM, "Effective clearance of methotrexate using high-flux hemodialysis membranes", Am J Kidney Dis, 28, pp.846~854 (1996)
- Murashima M, "Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report", Am J Kidney Dis, 53, pp.871~874 (2009)